Pabinafusp alfa

• CAT Number: I041028
• CAS Number: 2140211-48-7
• Purity: ≥95%

Pabinafusp alfa(CAT: I041028) is an investigational enzyme replacement therapy designed to treat patients with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. This innovative treatment provides a recombinant form of the enzyme iduronate-2-sulfatase, which is deficient in patients with MPS II. By replenishing the missing enzyme, Pabinafusp alfa helps to break down accumulated glycosaminoglycans (GAGs) that cause cellular and tissue damage. The treatment has shown potential to reduce GAG buildup, improve organ function, and enhance the quality of life for individuals suffering from this rare and progressive genetic disorder.